PDCD1 and neoplasm: Furthermore, tumors which have a higher number of cellular mutations are more likely to respond to CTLA-4/PD-1 blockade, since there is a higher likelihood that one or more of the tumor mutations will produce a novel epitope which can be recognized by T cells [34, 35].